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ABSTRACT
When Justice Harlan penned his opinion in Jacobson v.
Massachusetts, the landmark case setting the paradigm for when states
can mandate vaccination, he never imagined the innovative and unique
vaccines that technology would produce in subsequent decades. Now, as
new vaccines (such as the human papillomavirus vaccine) emerge that
fit outside the bounds of precedential case law, state legislatures and
courts face new territory when determining in what situations the need
to protect public health via vaccination outweighs an individual’s
constitutionally-guaranteed rights. This Article explores the current
process used when assessing vaccines that lay outside the Jacobson
paradigm. Further, this Article critiques that process and argues that,
when no set precedent exists, policy should be driven by those who are
not swayed by social, cultural, religious, political, or economic factors.
Instead, policy-makers should be those who can craft their decisions
with an unbiased and scientifically-driven aim, one that will objectively
weigh the interests of public health and private rights.

INTRODUCTION
On July 17, 1902, Henning Jacobson, facing a small fine,
adamantly refused to be vaccinated for smallpox pursuant to a mandate
ordered by the Board of Health of Cambridge, Massachusetts.
Trumpeting his rights to “life, liberty and property,” Jacobson battled
his way to the United States Supreme Court and for two-and-a-half
years, managed to avoid the vaccine. Then, in December of 1904, the
Supreme Court found for the Board of Health, holding that the Board’s
need to protect the public health and safety vindicated the compulsory
vaccination law.
With Jacobson began a long history of courts empowering states to
impose compulsory vaccination laws. Through Jacobson, the Supreme
Court set a precedent that has provided the framework by which states
determine when compulsory vaccination is appropriate. Since Jacobson,
courts have readily upheld state compulsory vaccination laws for
measles, smallpox, poliomyelitis, rubella, varicella, and other highly
contagious and deadly diseases.
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However, states’ authority to create these laws is not always so
clear. The less danger and imminence a given disease poses to the
public health, the less necessary a compulsory vaccine is. This
correlation inspires the question: what types of characteristics must a
disease have to justify the invasion of an individual’s rights to “life,
liberty, and property” by mandating a vaccine? With the emergence of
vaccines made for non-contagious but nonetheless prevalent and
dangerous diseases (for example, the human papillomavirus (HPV)
vaccine), the issue of state compulsory vaccination laws has become
riddled with controversy. Mandating the HPV vaccine has caused a
particularly heated debate due to the disease’s origins as a sexually
transmitted infection (STI).
As vaccines stray further from the Jacobson paradigm, state
legislatures (which create mandatory vaccination laws) are given
broader discretion for determining which vaccines should be mandatory.
This process becomes especially disconcerting when controversial
vaccines, such as the HPV vaccine, are used as political tools for
garnering constituent votes.
Through the lens of the HPV vaccine, this Article discusses the
process of mandating vaccines and asks who should be making those
policy decisions. This Article proceeds in seven parts. Parts I, II, and III
are predominantly dedicated to background and historical information
critical to evaluating the way compulsory vaccination laws are treated
today. Part I provides a background of HPV and its vaccine. Part II lays
out the history of compulsory vaccination laws and describes the current
paradigm for when mandatory vaccination is justified by public health
and safety needs. Part III illustrates how the HPV vaccine does not fit
within the existing paradigm.
Parts IV through VII transition into discussing how changes to the
current policy-making process would lead to objective policies not
swayed by social or economic pressures. Part IV discusses the current
process for mandating a vaccine. Part V lists the problems with the
current process, beginning with a discussion of social, cultural, and
religious pressures faced by state representatives, followed by an
explanation of how economic pressures play a role in the decisionmaking process as well. Part VI advocates for empowering other entities
with policy-making authority so that they might offer a less-biased
position on health policy decisions. Lastly, Part VII gives a brief
introduction to a final consideration – accountability – that should be
taken into account when deciding who should make these types of
health policy decisions.
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This Article makes no conclusions as to who should be making the
decisions behind compulsory vaccination laws. However, it opens the
discussion for reworking the process and incorporating other decisionmaking entities into the process. As this Article illustrates, the current
process is too susceptible to social and economic pressures, and health
policy should be premised on an unbiased, unclouded perspective that
discerns the true needs of the public regarding safety and health.
I. HPV AND ITS VACCINE
HPV infects 6.2 million new people each year just in the United
1
2
States, making HPV the most common STI in the United States.
Globally, 50 percent of people who have had sex in their lifetime will
3
be infected with HPV. In one study conducted in the United Kingdom,
researchers found that even of women with only one lifetime sexual
partner, 46 percent will acquire HPV within three years of becoming
4
sexually active. While for most, HPV is innocuous, for others, HPV can
lead to cervical cancer or genital warts. Specifically, HPV strains 16 and
18 reportedly cause 70 percent of cervical cancer cases and have also
5
been attributed to anal, vulvar, vaginal, penile, and urethral cancers.
HPV strains 6 and 11 cause 90 percent of anogenital warts and have
6
also been attributed to recurrent respiratory papillomatosis.
In June 2006, the United States Food & Drug Administration
(FDA) announced its approval of Merck’s Gardasil®, the first vaccine
7
against HPV, and in October 2009, the FDA announced its approval of
8
GlaxoSmithKline’s Cervarix®, another HPV vaccine. Gardasil®
1

Lawrence O. Gostin & Catherine D. DeAngelis, Mandatory HPV Vaccination: Public
Health vs Private Wealth, 297 J. AM. MED. ASS’N 1921, 1921 (2007).
2
Eileen F. Dunne et al., Prevalence of HPV Infection Among Females in the United
States, 297 J. AM. MED. ASS’N 813, 813 (2007).
3
Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/std/hpv/stdfact-hpv.htm (last modified Aug. 9, 2012).
4
Stuart Collins et al., High Incidence of Cervical Human Papillomavirus Infection in
Women During Their First Sexual Relationship, 109 BJOG 96, 96 (2002).
5
Gail Javitt, Deena Berkowitz, & Lawrence O. Gostin, Assessing Mandatory HPV
Vaccination: Who Should Call the Shots? 36 J.L. MED. & ETHICS 384, 385 (Summer 2008).
6
Id.
7
Letter from Norman W. Baylor, Director of Office of Vaccines, U.S. Food & Drug
Administration, to Patrick Brill-Edwards, Director of Worldwide Regulatory Affairs, Merck
&
Co.,
Inc.
(June
8,
2006),
available
at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm
[hereinafter Approval Letter (Gardasil) (June 8, 2006)].
8
Letter from Norman W. Baylor, Director of Office of Vaccines, U.S. Food & Drug
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protects against HPV strains 6, 11, 16, and 18, while Cervarix® protects
10
only against strains 16 and 18. Although clinical data has not yet
proven that the HPV vaccine prevents cervical cancer, the HPV vaccine
is nearly 100 percent effective at guarding against infections associated
11
with HPV.
Subsequent to these FDA approvals, the Centers for Disease
Control and Prevention (CDC), through its Advisory Committee on
Immunization Practices (ACIP), issued recommendations regarding
these vaccines. On June 29, 2006, the ACIP recommended that the HPV
vaccine be routinely given to girls aged eleven to twelve years old, but
noted that the vaccine can be given to girls as early as nine years old
12
and as late as twenty-six years old. The CDC has made additional
recommendations relating to the use of the vaccine by boys. Following
the FDA’s approval of the vaccine for use in boys ages nine to twenty13
six years old, the CDC recommended that, similar to young girls, the
vaccine should be routinely given to boys aged eleven to twelve years
old, but could also be administered to boys as young as nine years and
14
as old as twenty-six. Professional medical associations, including the
American Academy of Pediatrics, have recommended use of the vaccine
15
for adolescent girls when appropriate.

Administration, to Matthew Whitman, GlaxoSmithKlein Biologicals (Oct. 16, 2009),
available
at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm
[hereinafter Approval Letter (Cervarix) (Oct. 16, 2009)].
9
Approval Letter (Gardasil) (June 8, 2006), supra note 7.
10
Approval Letter (Cervarix) (Oct. 16, 2009), supra note 8.
11
Lawrence O. Gostin, Mandatory HPV Vaccination and Political Debate, 306 J. AM.
MED. ASS’N, 1699, 1700 (2011).
12
Press Release, The Centers for Disease Control & Prevention, CDC’s Advisory
Committee Recommends Human Papillomavirus Virus Vaccination (June 29, 2006),
available at http://www.cdc.gov/media/pressrel/
r060629.htm.
13
Letter from Wellington Sun, Director of Division of Vaccines, U.S. Food & Drug
Administration, to Patrick Brill-Edwards, Merck & Co., Inc. (Oct. 16, 2009), available at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm
[hereinafter Approval Letter (Gardasil) (Oct. 16, 2009)].
14
Press Briefing Transcript, ACIP Recommends All 11-12 Year-Old Males Get
Vaccinated Against HPV, CTRS. FOR DISEASE CONTROL & PREVENTION (Oct. 25, 2011),
available at http://www.cdc.gov/media/releases/2011/t1025_hpv_12yroldvaccine.html.
15
Gostin, supra note 11, at 1700.
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II.

POLICE POWERS: THE ESTABLISHED PARADIGM

Since the FDA approved Gardasil®, forty-one state legislatures
16
have proposed HPV vaccine-related legislation. Only Texas, Virginia,
and the District of Columbia have successfully imposed state
17
mandates. Virginia, for example, requires all girls to have received at
least the first dose of the HPV vaccine before they enter the sixth
18
grade. Although other states do not have mandatory vaccination laws,
they have implemented public education, free vaccination, and other
19
programs to promote the HPV vaccine.
States have the authority to implement compulsory vaccination
20
legislation through constitutionally-provided police powers. Through
police powers, states can create “such reasonable regulations established
directly by legislative enactment as will protect the public health and the
21
public safety.” It was first established that state compulsory
vaccination laws were protected by police powers in the landmark case
22
Jacobson v. Massachusetts. In Jacobson, the Supreme Court upheld a
Massachusetts law mandating smallpox vaccination where such
23
vaccination was “necessary for the public health or the public safety.”
In Zucht v. King, the Supreme Court affirmed “that it is within the
police power of a state to provide for compulsory vaccination” when
24
required for public health.
Certainly, precedent has firmly established that where states have a
legitimate public health goal, states can exercise police powers to create
compulsory vaccination laws. But what constitutes a legitimate public
health goal?
The decision in Jacobson highlighted that legitimate public health
goals are those that protect the community as a whole. As the Court
stated in Jacobson, “[t]here are manifold restraints to which every
25
person is necessarily subject for the common good.” For vaccines,
underlying this need to serve the common good is a concept called
16
17
18
19
20
21
22
23
24
25

Id.
Id. The Texas law, however, was subsequently revoked.
VA. CODE ANN. § 32.1 (2007).
Gostin, supra note 11, at 1700.
U.S. CONST. amend. X.
Jacobson v. Massachusetts, 197 U.S. 11, 25 (1905).
Id.
Id. at 27.
Zucht v. King, 260 U.S. 174, 176 (1922).
Jacobson, 197 U.S. at 26 (emphasis added).
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“herd immunity,” which is defined as:
[w]hen a sufficiently large proportion of individuals in a community
is immunized, those persons serve as a protective barrier against the
likelihood of transmission of the disease in the community, thus
indirectly protecting those who are not immunized and those who
26
received the vaccine but are not protected (vaccine failures).

In other words, even when some individuals are not immunized, disease
27
transmission is hampered when the overall community is immunized.
For a disease like smallpox (the subject of Jacobson), the benefits
of compulsory vaccination are immediately apparent because
community vaccination contributes to the establishment of herd
immunity. Smallpox is highly contagious because it is readily
28
transmitted through face-to-face contact and contact with bodily fluids.
Although rarely, smallpox can also be transmitted through air in
29
enclosed settings, such as buildings, buses, and trains. Once infected,
the disease is largely untreatable as soon as symptoms emerge (one to
30
four days after exposure), and the disease can be fatal. Further,
smallpox can only be transmitted between humans; there are no insect
31
or animal hosts. Accordingly, without human hosts, the disease cannot
be transmitted. Indeed, the efforts to eradicate smallpox through
compulsory vaccination have been successful with one hundred percent
32
eradication since 1977.
State eradication programs for diseases with features similar to
those of smallpox have likewise been found to promote public health
and safety because they contribute to herd immunity. Various courts
have upheld state compulsory vaccination laws for measles, diphtheria
33
toxoid, poliomyelitis, rubella, mumps, and other diseases. Measles, for
example, like smallpox, is highly contagious with the estimate that if
26
Kevin M. Malone & Alan R. Hinman, Vaccination Mandates: The Public Health
Imperative and Individual Rights, in LAW IN PUBLIC HEALTH PRACTICE 262, 264 (Richard A.
Goodman et al. eds., 2003).
27
Margaret J. Kochuba, Public Health vs. Patent Rights: Reconciling Informed Consent
with HPV Vaccination, 58 EMORY L.J. 761, 765 (2009).
28
Smallpox Disease Overview, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://emergency.cdc.gov/agent/smallpox/overview/disease-facts.asp (last modified Dec. 30,
2004).
29
Id.
30
Smallpox,
A.D.A.M.
MED.
ENCYCLOPEDIA,
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002332/ (last visited Nov 30, 2012).
31
Smallpox Disease Overview, supra note 28.
32
Malone & Hinman, supra note 26, at 265.
33
Id. at 270.
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one person contracts measles, ninety percent of people close to that
34
individual will also get infected. Further, measles can be highly fatal;
today, 164,000 people per year die of measles, despite immensely
35
successful eradication programs. The disease can only be transmitted
36
by humans. The measles vaccine was introduced in 1963, and by 1983,
37
all states had mandatory measles vaccine laws. One court found that,
“given the characteristics of measles,” the Arizona State Health
Department was authorized to adopt measures, including prohibiting
unvaccinated children from attending school, to protect the public from
38
a measles outbreak.
However, not all diseases fit so neatly into the category of diseases
that warrant mandatory vaccination laws. Not all diseases are so highly
contagious, highly fatal, or narrowly transmitted (e.g. transmitted only
by humans) as smallpox or measles and therefore, cannot be justified by
the concept of herd immunity. As courts are presented with such
diseases, they must stray from the paradigm established by Jacobson to
find justification for compulsory vaccination laws established to prevent
these diseases.
In Boone v. Boozman, the court was presented with such a decision
when a plaintiff brought suit alleging that mandatory hepatitis B
39
vaccination was unconstitutional. Although hepatitis B is fatal in about
40
one percent of cases and highly contagious, it is distinct from measles
or smallpox in that it is most commonly transmitted by affirmative
action on the part of the infected, e.g. unprotected sex or intravenous
41
drug use. Nonetheless, the court found that,
[although] Hepatitis B may not be airborne like smallpox . . . this is
not the only factor by which a disease could be judged dangerous.
Hepatitis B is spread by bodily fluids; the virus is “fairly hearty and

34
Transmission of Measles, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/measles/about/transmission.html (last modified Aug. 31, 2009).
35
Overview of Measles Disease, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/measles/about/overview.html (last modified Apr. 13, 2012).
36
Transmission of Measles, supra note 34.
37
Malone & Hinman, supra note 26, at 271.
38
Maricopa Cty. Health Dep’t v. Harmon, 156 Ariz. 161, 166 (Ariz. Ct. App. 1987).
39
Boone v. Boozman, 217 F. Supp. 2d 938, 952-54 (E.D. Ark. 2002).
40
Hepatitis
B,
A.D.A.M.
MED.
ENCYC.,
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001324/ (last visited Nov. 30, 2012).
41
Hepatitis
B,
CTRS.
FOR
DISEASE
CONTROL
&
PREVENTION,
http://www.cdc.gov/hepatitis/chooseb.htm (last modified Apr. 1, 2008).

2012]

COMPULSORY VACCINATION LAWS

9
42

can survive on surfaces, door knobs, et cetera, for up to a month.”

The court further held that “[i]mmunization of school children against
hepatitis B has a real and substantial relation to the protection of the
43
public health and the public safety.”
Similarly, tetanus is highly fatal (leading to death in one out of ten
44
cases ) but is not at all transmittable between people. Rather, tetanus is
caused by the bacteria C. Tetani that enters the body through injuries or
wounds, hence its association with rusty nails and other piercing metal
45
objects. Thus, herd immunity is a complete impossibility for tetanus,
46
and yet, forty-nine states mandate tetanus vaccination, the reason
perhaps being the grisly consequences of contracting tetanus. Tetanus
“do[es] not fit the ‘paradigm’ for compulsory vaccination . . . yet
declaring the tetanus mandate laws unconstitutional under Jacobson
could lead to needless cases of the gruesome lockjaw caused by the
47
disease.” Through hepatitis B and tetanus, courts have opened the door
to state mandates for vaccines that fit outside of the Jacobson paradigm.
III. THE HPV VACCINE:STEPPING OUTSIDE THE PARADIGM
No court has yet had the opportunity to review mandatory HPV
vaccine laws for their constitutionality. In March 2010, a pro se plaintiff
brought suit against the United States Government, challenging the
distribution of the HPV vaccine in public schools in the District of
48
Columbia. The case was successfully dismissed in favor of the
49
Government for lack of standing.
Despite the dearth of common law, when assessing the
characteristics of HPV, it is evident that HPV more closely aligns with
hepatitis B and tetanus, rather than with smallpox or measles. Thus,
HPV falls outside of the Jacobson paradigm that protects state
compulsory vaccination laws justified by herd immunity.
42

Boone, 217 F. Supp. 2d at 954 (internal quotations omitted).
Id.
44
Tetanus (Lockjaw) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm#disease (last modified Jan. 19,
2012).
45
Tetanus,
A.D.A.M.
MED.
ENCYC.,
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001640/ (last visited Nov. 30, 2012).
46
Malone & Hinman, supra note 26, at 270.
47
Case Note, Toward a Twenty-First-Century: Jacobson v. Massachusetts, 121 HARV.
L. REV. 1820, 1838 (2008).
48
Ndaba v. Obama, 697 F. Supp. 2d 75, 76 (D.C. 2010).
49
Id. at 78.
43
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Contagiousness

Unlike measles and smallpox, HPV is not easily communicable.
The virus resides in an individual’s epithelial (a.k.a. skin) cells,
particularly in mucous membranes, such as the genital areas, and is
50
transmitted by contact with the infected area. This means that HPV is
largely transmitted by affirmative actions, namely vaginal, oral, and
51
anal sex. Contagion, in and of itself, does not prevent a disease from
warranting compulsory vaccination laws, as could be seen with hepatitis
B and tetanus. However, unlike hepatitis B and tetanus, HPV is not a
robust virus that can reside on surfaces or doorknobs. HPV is relegated
to skin cells and thus, is truly limited in its ability to transmit.
B.

Fatality

Although HPV is quite prevalent, genital warts, cervical cancer,
52
and other types of cancers only occur in ten percent of HPV cases. Of
the diseases caused by HPV, cervical cancer is the most common with
twelve thousand new cases of cervical cancer each year in the United
53
States. A study conducted in 2007 (the most recent data available)
54
showed that four thousand women die each year from cervical cancer,
equating to a morbidity rate of 2.4 deaths per one hundred thousand
55
women. To put that in context, in the three years before the measles
vaccine was licensed in 1963, the average annual morbidity for children
afflicted with measles in the United States was over five hundred
56
thousand. Further, incidence rates of cervical cancer continue to fall
due to the development and greater availability of screening and
treatment services. Since the 1960s, cervical cancer incidence rates have

50

Debbie Bridges, Information About the Human Papillomavirus (HPV), WEBMD,
http://www.webmd.com/sexual-conditions/hpv-genital-warts/hpv-virus-information-abouthuman-papillomavirus (last viewed Nov. 13, 2012).
51
Id.
52
Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/std/hpv/stdfact-hpv.htm (last modified Aug. 9, 2012).
53
Id.
54
Cervical Cancer Statistics, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/cancer/cervical/statistics/index.htm (last modified Apr. 30, 2012)
(citing U.S. Cancer Statistics Working Group, United States Cancer Statistics: 1999–2007
Incidence and Mortality Web-based Report, CTRS. FOR DISEASE CONTROL & PREVENTION,
available at http://www.cdc.gov/uscs (last viewed Nov. 13, 2012)). (full site)
55
SEER Stat Fact Sheets: Cervix Uteri, NAT’L
CANCER
INST.,
http://seer.cancer.gov/statfacts/html/cervix.html (last viewed Nov. 13, 2012).
56
Malone & Hinman, supra note 26, at 266.
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fallen by seventy-five percent because cytology screening (the “Pap
smear”) was introduced and has become standard in women’s health
57
care.
C.

Modes of Transmission

Like measles and smallpox, HPV is transmitted between humans.
However, thus far, no state mandates the HPV vaccine for men, despite
58
the FDA having approved the vaccine for men in December 2010. For
herd immunity to be successful, immunization levels must reach a
specified threshold to protect the total number of susceptible
59
individuals. As an example, a study in Brazil showed that nearly 100
percent immunization of infants, coupled with subsequent yearly
vaccination of these infants for eight to nine years, was necessary to
60
interrupt the transmission of poliomyelitis there. While there is no
indication of what immunization level is required for eradication of
HPV to be successful, the lack of any mandates for men would at the
very least make the eradication process slower, if not make eradication
entirely impossible.
D.

Summary

On the other hand, HPV hosts other characteristics that suggest that
a compulsory vaccination law might be necessary. First, HPV is highly
prevalent with at least fifty percent of sexually active men and women
61
contracting it in their lifetime. Second, the disease is asymptomatic for
62
ninety percent of people, which means that people can transmit HPV
during sexual intercourse without even knowing that they carry the
virus. Lastly, because the virus resides in skin cells that may not be
covered by a condom, individuals can contract HPV even when they
63
think they are engaging in “safe sex.”
57
Vivien Davis Tsu, Overcoming Barriers and Ensuring Access to HPV Vaccines in
Low-Income Countries, 35 AM. J.L. & MED. 401, 402 (2009).
58
Letter from Wellington Sun, Director of Division of Vaccines, U.S. Food & Drug
Administration, to Patrick Brill-Edwards, Merck & Co., Inc. (Dec. 22, 2010), available at
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm238074.htm
[hereinafter Approval Letter (Gardasil) (Dec. 22, 2010)].
59
T. Jacob John & Reuben Samuel, Herd Immunity and Herd Effect: New Insights and
Definitions, 16 EUR. J. OF EPIDEMIOLOGY 601, 602 (2000).
60
Id.
61
Genital HPV Infection – Fact Sheet, supra note 52.
62
Id.
63
Bridges, supra note 50.
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Despite these characteristics, HPV does not lend itself to a
mandatory vaccination law to the same extent that measles or smallpox
does. Moreover, the HPV vaccine does not lend itself to a mandatory
vaccination law even to the same extent that hepatitis B or tetanus does.
Thus, the question then becomes, when a disease falls outside of the
Jacobson paradigm and is not protected by the exceptions provided in
Boone, who decides whether the vaccine should be mandatory?
IV. VACCINES: FROM RECOMMENDING TO REQUIRING
Understanding the current process for making a vaccine mandatory
is necessary for evaluating who should be driving the process. While
mandating a vaccine may seem like a singular decision, the entire
process involves a series of discretionary choices from a variety of
government agencies and representatives, starting with the FDA and
ending with state legislatures.
Vaccines, like any other medical product, must first go through
regulatory approval by the FDA. The FDA is a government agency
within the Department of Health and Human Services, and it is
“responsible for protecting the public health by assuring the safety,
efficacy and security of . . . drugs, biological products, [and] medical
64
devices . . . .” Under the Federal Food, Drug & Cosmetics Act, the
FDA holds the authority to review vaccines for safety and efficacy
before the maker of a vaccine is permitted to distribute the vaccine to
65
the public. Upon review, the FDA will either approve or deny a new
vaccine.
Once a vaccine has been approved, the Centers for Disease Control
and Prevention (the “CDC”) establishes written recommendations for
the administration of vaccines to the general public. The CDC is a
federal agency under the Department of Health and Human Services,
66
and a large part of its mission is to prevent disease. The CDC
specifically addresses vaccines through its Advisory Committee on
Immunization Practices (ACIP). The ACIP consists of fifteen
immunology experts (and additional non-voting members and liaisons)
who advise the Secretary of the U.S. Department of Health and Human

64

What
We
Do,
U.S.
FOOD
&
DRUG
ADMIN.,
http://www.fda.gov/aboutfda/whatwedo/default.htm (last modified June 19, 2012).
65
42 U.S.C. § 262 (2012).
66
Vision, Mission, Core Values, and Pledge, CTRS. FOR DISEASE CONTROL &
PREVENTION, http://cdc.gov/about/organization/mission.htm (last modified Jan. 11, 2010).
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Services, the Assistant Secretary for Health, and the CDC.
While one aspect of the CDC’s mission is to prevent disease,
another aspect is to “develop and advocate sound public health
68
policies.” As such, the CDC’s recommendations are often used by
states to develop legislation. In fact, while the CDC’s recommendations
are non-binding, the “power and prestige of the CDC and other
administrative heavy artillery easily intimidates state legislators and
even health care professionals who might otherwise deviate from the
69
official path.”
After the CDC issues a recommendation regarding a vaccine, state
representatives may propose a bill to state legislatures that will make the
vaccine mandatory. Alternatively, some state legislatures grant authority
70
to regulatory bodies, such as a Board of Health. In some cases, state
governors issue executive orders, which subsequently must pass through
the state legislature. In any case, the bill must ultimately pass through
the state legislature, which holds the power to mandate a vaccine
71
through its constitutionally-provided police powers. Police powers
give states the authority to create “such reasonable regulations
established directly by legislative enactment as will protect the public
72
health and the public safety.”
V. SOCIAL, ECONOMIC, AND OTHER PRESSURES:
PROBLEMS WITH THE CURRENT METHOD
Currently, state representatives (whether state legislators or
governors) are driving the policies behind mandatory vaccination. Of
course, the nature of state representatives is that they are elected by their
state constituents, which draws concern when assessing how effective
representatives are at determining the best interests of the general public
in terms of health and safety. A decision incentivized by social or
economic pressures may not accurately reflect the best interests of the
public.

67
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ACIP,
CTRS.
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&
PREVENTION,
http://www.cdc.gov/vaccines/acip/about.html (last modified Aug. 16, 2012).
68
Vision, Mission, Core Values, and Pledge, supra note 66.
69
KURT LINK, THE VACCINE CONTROVERSY: THE HISTORY, USE, AND SAFETY OF
VACCINATIONS 171 (2005).
70
Richard Hughes, IV, Using Law, Policy, and Research to Improve the Public’s
Health, 39 J.L. MED. & ETHICS 37, 37 (2011).
71
U.S. CONST. amend. X.
72
Jacobson, 197 U.S. at 25.
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Social, Cultural, and Religious Pressures

State representatives may seek to represent the interests of their
constituents; however, to begin with, the general public is largely
uninformed when it comes to HPV. A national survey conducted in
2000 found that less than two percent of Americans know that HPV is
73
an STI. Although public knowledge about HPV has increased since the
introduction of the vaccine, knowledge is nonetheless limited, and the
majority of women are still unaware of the link between HPV and
74
cervical cancer. As a result, the public depends on sources like health
agencies, pharmaceutical companies, special interest groups, the media,
and the internet for information, and these sources are largely
75
conflicting and furthermore, biased. On that point, because non-profit
organizations, the CDC, and public health organizations have limited
budgets and resources, the vaccine manufacturers (those with the
biggest budgets) are best able to reach audiences, leaving public
education in the hands of Merck and GlaxoSmithKline, companies that
76
have been accused of heavily skewing the data.
To add to the misperceptions surrounding HPV, HPV is a largely
stigmatized disease, mostly because it elicits the taboo topic of sexual
77
health. In one study, participants were asked to list words they
associated with sexually transmitted diseases, and the most common
words named were promiscuity, infidelity, shame, embarrassment, guilt,
78
and divorce. In the United States, there is a strong belief that
mandating an HPV vaccine will encourage young girls to become
79
sexually active at an early age and will encourage sexual promiscuity.

73
Allison L. Friedman & Hilda Shepeard, Exploring the Knowledge, Attitudes, Beliefs,
and Communication Preferences of the General Public Regarding HPV: Findings From
CDC Focus Group Research and Implications for Practice, 34 HEALTH EDUC. BEHAV. 471,
472 (2007).
74
Id.
75
Id.
76
Ilene Albala, Mandatory HPV Vaccination: Is There a Happy Medium? 12 U. PA. J.L.
& SOC. CHANGE 221, 244 (2008-2009).
77
Suellen Hopfer & Jessie R. Clippard, College Women’s HPV Vaccine Decision
Narratives, 21 QUALITATIVE HEALTH RES. 262, 262-63 (2011).
78
Friedman & Shepeard, supra note 73, at 475.
79
See e.g., J. Waller et al., Mothers’ Attitudes Towards Preventing Cervical Cancer
Through Human Papillomavirus Vaccination: A Qualitative Study, 15 CANCER
EPIDEMIOLOGY BIOMARKERS & PREVENTION 1257, 1259 (2006); N. Liddon et al.,
Parents’/Guardians’ Willingness to Vaccinate Their Children against Genital Herpes, 37 J.
OF ADOLESCENT HEALTH 187 (2005).
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In addition to stigmatizing the disease, the public has stigmatized
the vaccine itself. There is a popular misperception that the vaccine is
unsafe, was not satisfactorily tested before FDA approval, and leads to
80
afflictions such as autism. On the contrary, the safety profile for the
HPV vaccine is quite robust. Clinical trials have been conducted with
81
over 59,000 participants, and as of January 2010, an estimated 28
million doses of Gardasil® alone had been administered in the United
82
States. As of June 2011, the only vaccine side effects reported to the
FDA were minor (dizziness, fainting, headache, nausea, and injectionsite reactions), and autism and other types of mental and development
83
disorders have never been reported.
Representatives making decisions regarding the HPV vaccine face
pressure due to these public perceptions. In February 2007, Governor
Rick Perry issued an executive order and singlehandedly mandated the
84
HPV vaccine in Texas for girls entering the sixth grade in 2007. Even
before Governor Perry introduced the action, the National Vaccine
Information Center (NVIC), a non-profit organization that has been
described as “the most powerful anti-vaccine organization in
85
America,” had begun its campaign to thwart implementation of a
86
mandatory HPV vaccine. The NVIC based its campaign on the premise
87
that Merck had failed to prove the safety of Gardasil ®. It was
successful, and only a few months later, in May 2007, the Texas
88
legislature voted to overturn Governor Perry’s executive order.
80

See e.g., Press Release, National Vaccine Information Center, Merck’s Gardasil
Vaccine Not Proven Safe for Little Girls (June 27, 2006), available at
http://www.nvic.org/nvic-archives/pressrelease/gardasilgirls.aspx.
81
Human Papillomavirus (HPV) Vaccine, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index.html#data (last modified Oct. 21,
2012).
82
Claudia Vellozzi, CDC Commentary: New Safety Data on the HPV Vaccine –
Reassuring Your Patients, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.medscape.com/viewarticle/722555 (last visited Nov. 26, 2012).
83
Information from FDA and CDC on Gardasil and its Safety, CTRS. FOR DISEASE
CONTROL & PREVENTION, http://www.cdc.gov/vaccinesafety/vaccines/HPV/Index.html (last
visited Dec. 23, 2012).
84
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Exec.
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No.
RP65
(Feb.
2,
2007),
available
at
http://governor.state.tx.us/news/executive-order/3455/.
85
MICHAEL SPECTER, DENIALISM: HOW IRRATIONAL THINKING HINDERS SCIENTIFIC
PROGRESS, HARMS THE PLANET, AND THREATENS OUR LIVES 7 (2009).
86
See e.g., Merck’s Gardasil Vaccine Not Proven Safe for Little Girls, supra note 80.
87
Id.
88
2007 Tex. Gen. Laws 43 § 1 (amending TEX. EDUC. CODE ANN. § 38.001 (West
2007)) (girls entering sixth grade no longer required to receive HPV vaccination effective
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Even recently, as Governor Perry ran for the Republican
Presidential ticket, his campaign reopened old wounds. While Governor
Perry defended his decision to mandate the vaccine in 2007, his
opponents fueled common false beliefs and perpetuated the HPV
vaccine stigma. For example, during the Republican Presidential debate
held September 12, 2011, Republican Presidential candidate Michele
Bachmann argued,
to have innocent little 12-year-old girls be forced to have a
government injection through an executive order is just flat out
wrong . . . little girls who have a negative reaction to this potentially
dangerous drug don’t get a mulligan. They don’t get a do-over. The
89
parents don’t get a do-over.

One day later, in an interview on the Today Show, Ms. Bachmann
stated,
Well, I will tell you that I had a mother last night come up to me here
in Tampa, Florida after the debate and tell me that her little daughter
took that vaccine, that injection, and she suffered from mental
90
retardation thereafter. It can have very serious side effects.

Representatives seeking to please constituents may play into these
social and cultural beliefs just to get a vote, and in fact, research shows
that their strategy may not be entirely without merit. Voters are more
likely to vote according to their moral beliefs because of the low cost of
91
voting and the absence of any significant effect on the voter’s interests.
Furthermore, because HPV relates to sexual health, it may get lumped
with other single-issue voting topics, such as abortion.
B.

Economic and Political Pressures

When issuing his executive order, Governor Perry faced pressures
just as pervasive as social, cultural, and religious pressures; he
confronted economic pressures from the patent-holders, namely Merck.
The pharmaceutical and biotechnology industries are notoriously strong
May 8, 2007); see also Dan Frosch, Texas House Rejects Order by Governor on Vaccines,
N.Y.
TIMES,
Mar.
14,
2007,
available
at
http://www.nytimes.com/2007/03/14/us/14vaccine.html.
89
CNN Live Event/Special: Tea Party Republican Debate (CNN television broadcast
Sept. 12, 2011), http://archives.cnn.com/TRANSCRIPTS/1109/12/se.06.html.
90
The Today Show (MSNBC television broadcast Sept. 13, 2011),
http://today.msnbc.msn.com/id/44489617/ns/today-today_news/t/perry-assailed-rivalsforced-defend-record/.
91
Jonathan Baron, Preference and Rational Choice: New Perspectives and Legal
Implications, 151 U. PA. L. REV. 1135, 1142-43 (2003).
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lobbyists, and so their influence on law-making cannot be understated.
According to the Center for Responsive Politics, the drug lobby spent
93
over $2.5 billion in lobbying funds between 1998 and 2012. This
94
figure surpasses any other industry by more than 700 million dollars.
The HPV vaccine is unique because both vaccines available
(Gardasil® and Cervarix®) are still under patent, which provides the
manufacturers of these drugs a near monopoly on the market and
permits the manufacturers to charge high prices. Both vaccines require
95
three doses. For children, the CDC can provide Gardasil® at a cost of
$98.60 per dose and Cervarix® at a cost of $96.08 per dose, while the
private sector cost is $135.45 per dose for Gardasil® and $128.75 per
96
dose for Cervarix®.
Notably, there are no generic versions of the HPV vaccine in
development due to previously-existing rules that prohibited the
creation of follow-on biologics (which includes vaccines). The Patient
Protection and Affordable Care Act laid out instructions for the
Secretary of the Department of Health and Human Services and the
97
FDA to create a follow-on biologics regulatory pathway. The creation
of a generic HPV vaccine would ultimately reduce the cost of the
vaccine, but until then, patients are subject to high prices.
Due to this near monopoly on the market, Merck and
GlaxoSmithKline have great incentive to encourage states to pass
compulsory vaccination laws, and in fact, Merck has been actively
lobbying for state compulsory laws. According to records from New
York’s Temporary State Commission on Lobbying, Merck spent almost
400 thousand dollars between 2003 and 2006 on lobbying for
98
Gardasil®. The CDC has also implied that vaccine manufacturers have
92
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(Dec.
17,
2009,
8:58
AM),
http://www.npr.org/blogs/health/2009/12/pharma_friends_an_analysis.html.
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http://www.opensecrets.org/lobby/top.php?showYear=a&indexType=i (last viewed Nov.
13, 2012).
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Id.
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&
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http://www.cdc.gov/hpv/vaccine.html (last modified Mar. 21, 2012).
96
CDC Vaccine Price List, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/pricelist/index.html (last modified Nov. 1, 2012).
97
H.R. 3590, 111th Cong. § 7002(f)(1)(A) (2009).
98
Tracy Solomon Dowling, Mandating a Human Papillomavirus Vaccine: An
Investigation into Whether Such Legislation is Constitutional and Prudent, 34 AM. J.L. &
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heavily influenced the adoption of mandatory HPV laws. According to
Governor Perry, Merck only donated 5,000 dollars to his gubernatorial
campaign at the time he issued the executive order mandating the HPV
100
vaccine in Texas. In reality, Merck donated $28,500 to his
gubernatorial campaign and $377,500 to the Republican Governors
101
Association, an organization for which Governor Perry served as
Chairman and whose mission it is to help elect Republican candidates to
102
governorships throughout the country.
Despite this apparent conflict of interest, Governor Perry had other,
less controversial economic pressures that weighed towards the passage
of a compulsory vaccination law. The costs of HPV-related diseases are
staggering, with an estimated $4 billion in annual direct medical costs
103
for the prevention and treatment of genital warts and cervical cancer.
That $4 billion is comprised of the following estimates of annual direct
medical costs: cervical cancer ($300-400 million), cervical
intraepithelial neoplasia ($700 million-$2.3 billion), anogenital warts
104
($200 million), and routine cervical cancer screening ($2.3 billion).
The total excludes lost productivity costs and medical costs attributed to
other HPV-related diseases, such as anal, penile, vaginal, and vulvar
105
cancers.
Even with such high costs related to the treatment and prevention
of cervical cancer and genital warts, drug industry lobbying reflects
poorly on state representatives’ ability to make unbiased decisions when
106
it comes to public health.
MED. 65, 82 (2008).
99
Kathryn M. Edwards, State Mandates and Childhood Immunization, 284 J. AM. MED.
ASS’N 3171, 3171 (2000).
100
Gostin, supra note 11, at 1700.
101
Id.
102
Governor Rick Perry Elected Chairman of the Republican Governors Association,
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GOVERNORS
ASS’N,
http://rgaorg.myrga.org/index.php?option=com_content&view=article&id=18:governor-rick-perryelected-chairman-of-the-republican-governors-association&catid=1:pressreleases&Itemid=5 (last viewed Nov. 12, 2012); About, REPUBLICAN GOVERNORS ASS’N,
http://www.rga.org/homepage/about/, (last viewed Nov. 12, 2012).
103
Ralph P. Insinga, Erik J. Dasbach & Elamin H. Elbasha, Assessing the Annual
Economic
Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in
the US: Analytic Framework and Review of the Literature, 23 PHARMACOECONOMICS 1107,
1108 (2005).
104
Id.
105
Id.
106
Gostin, supra note 11, at 1700.
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VI. UNBIASED ENTITIES: MOVING TOWARDS AN
OBJECTIVE DECISION-MAKING PROCESS
State representatives are subject to an immense amount of pressure
that draws into question their ability to effectively make decisions
regarding the public’s health and safety. When presented with vaccines
that fall outside of the Jacobson paradigm, is it best to defer policymaking decisions to other more objective entities? The FDA, the CDC,
the ACIP, and professional medical associations could potentially fill
that role; however, each entity faces its own set of political pressures
and areas of vulnerability that make it arguably unsuitable for such
policy-making.
A.

The FDA

When considering other entities that could assume the
responsibility of developing compulsory vaccination policies, the FDA
is an immediately apparent choice. The FDA is historically a science107
based agency and was originally responsible for the HPV vaccine’s
approval. The FDA has followed Merck and GlaxoSmithKline through,
collectively, the administration of over 59,000 doses of the HPV
108
vaccine. It has been intimately involved in the approval of package
109
inserts and patient information pamphlets. The FDA receives and
110
reviews any and all adverse side effects reports. In summary, the FDA
holds an immense amount of information about the HPV vaccine and at

107

David C. Vladeck, The FDA and Deference Lost: A Self-Inflicted Wound or the
Product of a Wounded Agency? A Response to Professor O’Reilly, 93 CORNELL L. REV. 981,
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108
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(last
modified Dec. 30, 2009).
109
See, e.g., Letter from Wellington Sun, Director of Division of Vaccines and Related
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&
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(July
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2012),
available
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110
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ADMIN.,
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&
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least from a purely scientific point of view, could formulate a
conclusion regarding whether it should be mandatory.
Yet despite the FDA’s wealth of knowledge, the FDA is not
without bias. FDA agents lack any sort of sustained relationship with
consumers but regularly interact with pharmaceutical and biotechnology
111
manufacturers. This close relationship with the pharmaceutical and
biotechnology industries is all the more true because of the “revolving
door” which rotates FDA employees from the FDA to the
112
pharmaceutical and biotechnology industries and back again.
To make matters worse, senior appointees to FDA offices are
typically appointed for political reasons, and as such, senior appointees
marginalize the opinions of FDA scientists in exchange for the political
113
opinions of their appointers. Most recently, FDA Commissioner
Margaret Hamburg substituted the opinion of FDA scientists for the
wishes of Kathleen Sebelius, the Secretary of the Department of Health
114
and Human Services, regarding Plan B, an emergency contraceptive.
The Center for Drug Evaluation and Research (CDER), a division
within the FDA, reviewed Plan B to determine if it was safe as an over115
the-counter product for girls under seventeen years of age. CDER
116
determined that Plan B was in fact safe for those purposes.
Dr. Hamburg agreed, stating,
I reviewed and thoughtfully considered the data, clinical information,
and analysis provided by CDER, and I agree with the Center that
there is adequate and reasonable, well-supported, and science-based
evidence that Plan B One-Step is safe and effective and should be
approved for nonprescription use for all females of child-bearing
117
potential.

However, after receiving a memorandum from Secretary Sebelius
disapproving of CDER’s findings, Dr. Hamburg ordered Plan B to
118
remain prescription-only for girls under seventeen years old.
111

James T. O’Reilly, Drug Review “Behind the Curtain”: A Response to Professor
Struve, 93 CORNELL L. REV. 1075, 1079 (2008).
112
Vladeck, supra note 107, at 982.
113
Id.
114
Margaret Hamburg, Comm’r, Dept. of Health & Human Servs., U.S. Food & Drug
Admin., Statement on Plan B One-Step (Dec. 7, 2011) (transcript available at
http://www.fda.gov/NewsEvents/Newsroom/ucm282805.htm).
115
Id.
116
Id.
117
Id.
118
Id.
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The Plan B decision serves as a pointed example of how the FDA
is not immune to pressure from politicians and may not be the wholly
scientific authority it espouses itself to be. In addition, even if the FDA
had the authority to do so, determining whether a vaccine should be
mandatory may be outside the bounds of what is feasible for it both in
terms of its resources and its expertise.
B.

The CDC and the ACIP

The CDC and ACIP stand in a similar position as the FDA when it
comes to the broad scope of knowledge they hold regarding the HPV
vaccine. If anything, the CDC’s knowledge is even more comprehensive
than the FDA’s because the CDC has a thorough understanding of the
epidemiological context in which the HPV vaccine lies.
First, the CDC aims to “monitor health, detect and investigate
119
health problems, [and] conduct research to enhance prevention.”
When it comes to vaccines, maintaining a regularly and constantly
updated database that catalogues the distribution and coverage of
vaccines is critical to this goal. The CDC collects vaccination
information by two methods: the National Immunization Survey (NIS)
120
and school and childcare vaccination surveys.
The NIS first began in 1994 to track the immunization rates of
diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella,
121
and Haemophilus Influenza type B (whooping cough). Starting in
2006, the NIS created an on-going survey of HPV immunization
122
coverage among teens aged thirteen to seventeen years old. The
123
survey provides annual data from 2006 to 2011. The NIS has also put
together an adult study, which analyzes why some adults have chosen to
124
receive the HPV vaccine and why others have not.

119
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121
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The school and childcare vaccination surveys are a second datacollection method employed by the CDC. For those states that have
enacted compulsory vaccination laws, the CDC has asked those states to
125
report on vaccination coverage. As states review and assess
vaccination coverage in their own mandatory vaccination programs,
126
they report those findings to the CDC. These reports are mandatory
for any schools and childcare facilities that receive grants from the
127
CDC. Between the NIS and the school and childcare vaccination
surveys, the CDC has gathered extensive information about the
distribution and coverage of the HPV vaccine since its approval by the
FDA.
Second, the CDC has developed the Vaccine Management
Business Improvement Project (VMBIP). Through VMBIP, the CDC
performs a “top-to-bottom” assessment of the entire national
vaccination program, including everything from vaccine ordering to
128
vaccine distribution. The CDC has partnered with state and local
129
governments to review and improve the current vaccination process.
Through this program, the CDC has become familiar with HPV vaccine
supply, demand, and coverage and has aided states to develop
130
streamlined HPV vaccine management programs.
Third, the CDC has the biggest representation from various
medical, scientific, and industry organizations and associations.
Although the ACIP only consists of fifteen voting members, the
131
committee receives input from other non-voting members. The voting
members consist almost entirely of doctors, lawyers, and nurses who
specialize in immunology and currently serve as professors at various
132
universities across the country. The Ex Officio members, on the other
125

School and Childcare Vaccination Surveys, CTRS. FOR DISEASE CONTROL &
PREVENTION, http://www.cdc.gov/vaccines/stats-surv/schoolsurv/default.htm (last modified
June 20, 2011).
126
Id.
127
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modified Jan. 25, 2012).
128
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modified Nov. 20, 2009).
129
Id.
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Id.
131
About ACIP, supra note 67.
132
ACIP
Members,
CTRS.
FOR
DISEASE
CONTROL
&
PREVENTION,
http://www.cdc.gov/vaccines/recs/acip/members.htm (last modified Jul. 18, 2012).
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133

hand, are federal agency representatives. Moreover, the ACIP has
liaison representatives from numerous medical associations and
organizations, as well as the biotechnology and pharmaceutical
134
industries. While not all of these members are voting members, at
least the ACIP involves the opinions of experts from a broad spectrum
of medical fields.
Lastly, the CDC already has as part of its mission to “develop and
135
advocate sound public health policies.” Specifically, the ACIP’s role
is to
provide advice that will lead to a reduction in the incidence of
vaccine preventable diseases in the United States, and an increase in
the safe use of vaccines and related biological products. The
Committee develops written recommendations for the routine
administration of vaccines to children and adults . . . The ACIP is the
only entity in the federal government that makes such
136
recommendations.

Thus, the CDC and ACIP are already equipped with the expertise and
capabilities to make recommendations regarding vaccine mandates.
Despite the CDC and ACIP’s qualifications, they are subject to the
same criticisms as the FDA. To begin with, the voting members of the
ACIP are exposed to political pressure because they are all elected by

133

Id. Ex Officio members come from Centers for Medicare and Medicaid Services,
Department of Defense, Department of Veterans Affairs, Food and Drug Administration,
Health Resources and Services Administration, Indian Health Service, National Vaccine
Program Office, and National Institutes of Health.
134
Id. Liaison members come from American Academy of Family Physicians,
American Academy of Pediatrics, American Academy of Physician Assistants, American
College Health Association, American College of Obstetricians and Gynecologists,
American College of Physicians, American Geriatrics Society, America’s Health Insurance
Plans, American Medical Association, American Nurses Association, American Osteopathic
Association, American Pharmacists Association, Association of Immunization Managers,
Association for Prevention Teaching and Research, Association of State and Territorial
Health Officials, Biotechnology Industry Organization, Council of State and Territorial
Epidemiologists, Canadian National Advisory Committee on Immunization, Department of
Health (United Kingdom), Healthcare Infection Control Practices Advisory Committee,
Infectious Diseases Society of America, National Association of County and City Health
Officials, National Association of Pediatric Nurse Practitioners, National Foundation for
Infectious Diseases, National Immunization Council and Child Health Program (Mexico),
National Medical Association, National Vaccine Advisory Committee, Pharmaceutical
Research and Manufacturers of America, Society for Adolescent Health and Medicine, and
Society for Healthcare Epidemiology of America.
135
Vision, Mission, Core Values, and Pledge, supra note 66.
136
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the Secretary of the Department of Health and Human Services. In
addition, the CDC holds tight relationships with pharmaceutical and
biotechnology companies. To provide vaccines at discounted prices to
state and city immunization programs, the CDC enters into contracts
138
with vaccine manufacturers. In fact, the CDC is the largest purchaser
139
and distributor of vaccines. Although the CDC provides dozens of
different vaccines to immunization programs, these vaccines are
manufactured by a relatively small number of companies:
GlaxoSmithKline, MassBiologics, MedImmune, Merck, Novartis,
140
Pfizer, and Sanofi Pasteur. In effect, the CDC’s dedication to the
success of the immunization programs it assists may in some ways also
serve as its Achilles’ heel because it depends so heavily on these
pharmaceutical and biotechnology companies to provide vaccines at a
discounted rate.
The CDC and ACIP have been criticized in particular because of
their relationship with Merck and the HPV vaccine. At the time the
FDA approved the use of Gardasil®, Merck had only carried the vaccine
through three-and-a-half years of clinical trials with 12,000 patients,
141
which is a relatively small number. Many assailed the vaccine for not
being supported by sufficient safety and efficacy data, and yet, in the
same month as the FDA gave its stamp of approval, so did the CDC and
142
ACIP. Without addressing the low amount of clinical testing, the CDC
recommended that the vaccine be “routinely given to girls when they
143
are 11-12 years old.”
To add fuel to the fire, on January 25, 2010, Dr. Julie Gerberding
became President of Merck Vaccines after having served as the Director
144
of the CDC from 2002 to 2009. Dr. Gerberding’s tenure as CDC
Director included the time period that the CDC reviewed and
137
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139
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2009,
available
at
http://www.bizjournals.com/philadelphia/stories/2009/12/21/daily7.html.
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recommended the HPV vaccine. Her move to “big pharma” prompted a
flurry of charged and aggressive articles and blogs accusing Dr.
Gerberding of having been in the back pocket of Merck during her
145
entire time as CDC Director.
Whether or not the accusations against Dr. Gerberding are true,
certainly the CDC is not a stranger to the concept of the “revolving
door,” just as is true for the FDA. Unlike the FDA, however, the CDC
has this additional interdependent relationship with the pharmaceutical
and biotechnology industries, which draws further skepticism to the
CDC’s ability to remain an unbiased decision-making entity.
C.

Professional Medical Associations

Until recently, professional medical associations did not make
recommendations regarding the use of various drugs, biologics, and
146
other medications. However, it is not entirely out of the question that
perhaps they should. After all, physicians ultimately should care about
patient health and safety above all else. The mission statements of most
professional medical associations echo this sentiment. The American
Academy of Pediatrics “dedicate[s] their efforts and resources to the
health, safety and well-being of infants, children, adolescents and young
147
adults.” Likewise, the American Medical Association “promote[s] the
148
art and science of medicine and the betterment of public health.” This
commitment to the public health provides professional medical
associations with a uniquely objective perspective.
Because professional medical associations have only recently
started making vaccine recommendations, when state laws mandating
the HPV vaccine first started being proposed, state legislatures were
149
doing so without physician input. Now, many prominent professional
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medical associations, including the American Academy of Pediatrics,
the American Academy of Family Physicians, and the American
College of Physicians, have recommended the administration of the
150
vaccine to females aged eleven to twelve years old.
However, these professional medical associations largely shy away
from making recommendations regarding state mandates. The exception
is the American Medical Association, which allows physician
commentators to contribute to its Journal of the American Medical
Association (JAMA). It should be noted that the editorials published in
JAMA do not represent the opinions of the American Medical
Association; however, they do offer insight into the thoughts and
perspectives of individual physicians. For example, one article lauded
the potential of the HPV vaccine but strongly advised against
151
compulsory vaccination laws, calling them a “last resort.”
152
Physician perspectives given in JAMA vary greatly, and this
accurately reflects the fragmented opinions of physicians in general
regarding the HPV vaccine. In a study conducted by Medimix
International, a healthcare marketing research company, 57 percent of
physicians thought the HPV vaccine should not be mandated, even
though 97 percent of physicians believed that the HPV vaccine should
153
be administered.
In addition to the lack of unity among physicians regarding
mandatory HPV vaccination, an even greater concern is that, while
physicians may have their patients’ health in mind, they are nonetheless
susceptible to aggressive marketing tactics by large pharmaceutical and
biotechnology companies. Nowhere has this been truer than with
Merck’s hard-lined and novel marketing campaign for Gardasil®.
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Merck started by cherry-picking its disease. Fearing parent
opposition to a vaccine that immunized against sexually transmitted
disease, Merck chose instead to focus on HPV’s implications for
154
cervical cancer, and what parent would not want to protect his or her
daughter against cancer? Merck next appealed to a broad audience.
Rather than focus on highly susceptible populations, Merck
indiscriminately targeted every adolescent girl in America, inspiring
155
them to be “1 less” victim of cervical cancer. Merck successfully
made the HPV vaccine into a sensation, so much so that, in 2007,
shortly after the FDA approved Gardasil®, Pharmaceutical Executive
rewarded Gardasil® the “Brand of the Year” for having created a
156
“market out of thin air.”
Merck understood that the best method for reaching individual
consumers was through physicians, and it further realized that
physicians follow recommendations from professional medical
157
associations. Thus began a directed campaign by Merck to heighten
158
associations’ involvement in vaccine promotion. Merck provided
professional medical associations with funding, which these
associations then used for educational programs and Gardasil®-specific
159
speakers’ bureaus. Unsurprisingly, these educational programs and
speakers’ bureaus were one-sided, often omitting critical information
necessary for physicians to accurately determine if administering the
160
vaccine is best for their patients. Furthermore, Merck required these
161
associations to report back to it with progress updates.
Merck specifically targeted the following professional medical
associations: the American College of Obstetricians and Gynecologists,
the American Society for Colposcopy and Cervical Pathology
(ASCCP), the Society of Gynecologic Oncologists (SGO), and the
162
American College Health Association (ACHA). Each association in
turn developed a unique program with Merck’s donated funds. For
example, ASCCP developed an “Educate the Educators” program that

154
155
156
157
158
159
160
161
162

Rothman & Rothman, supra note 152, at 781.
Id. at 782.
Beth Herskovitz, Brand of the Year, 27 PHARM. EXEC. 58, 58 (2007).
Rothman & Rothman, supra note 152, at 782.
Id.
Id. at 781.
Id. at 781-85.
Id. at 785.
Id. at 783.

28

SETON HALL LEGISLATIVE JOURNAL

[Vol. 37:1
163

taught physicians how to educate the public about the vaccine. Each
physician who attended the program received a “Speaker Lecture Kit”
that provided a set of educational tools, including a 173-slide
164
PowerPoint presentation. The slideshow urged physicians to contact
local and state governments about funding the vaccine, encouraging
165
insurance companies to cover the vaccine, and mandating the vaccine.
The slideshow further advocated that physicians avoid discussing the
sexually transmitted aspect of HPV, if they feel that parents would be
166
uncomfortable doing so.
The SGO similarly developed a program that provided
incomprehensive, biased information to physicians. The SGO started an
HPV vaccine speakers’ bureau, which was comprised of panelists who
were financially connected to Merck and who drafted all of the lecture
167
materials. The speaker series puffed up the HPV vaccine’s notoriety as
“the first vaccine directed against a cancer,” while completely ignoring
168
the cautionary details. For example, the teaching materials failed to
provide comprehensive data on cervical cancer incidence rates and
declined to discuss secondary prevention methods, safety and efficacy
169
data, and potential risks.
Nowhere in any of the educational materials produced by these
professional medical associations did these associations mention their
170
connection to Merck or that Merck was funding their efforts. This lack
of transparency is disconcerting because it shows that these associations
are either being blindly manipulated or willingly eating out of the hands
of their donors, knowing that public health and safety may be at risk.
If professional medical associations are so willing to act as pawns
for the pharmaceutical industry, then they are ill-suited to make
recommendations to states regarding compulsory vaccination laws.
Professional medical associations should not be engaging in productspecific speakers’ bureaus or reporting their educational activity to
171
Merck (or any other industry donor). As their mission statements
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suggest, professional medical associations should be dedicated to
disseminating unbiased, scientifically-backed information that benefits
172
patients, not pharmaceutical companies. If associations can achieve
those ends, then perhaps they will emerge as authorities on state
compulsory vaccination laws.
VII. ACCOUNTABILITY: HOW DO WE HOLD FEDERAL
AGENCIES RESPONSIBLE FOR MANDATORY VACCINATION
LAWS?
This Article has proposed the idea of shifting decision-making
behind compulsory vaccination laws from state legislatures to another
entity, such as the FDA or the CDC. Both the CDC and FDA are armed
with a greater level of vaccine knowledge and familiarity than a state
legislature could ever hope to glean. Yet passing the buck from state
legislatures to federal agencies elicits discomfort because inevitably,
granting greater authority to a federal agency (like the FDA or CDC)
means stripping state legislatures of power. Part of this discomfort
stems from the federalist tradition that residual power in the United
173
States is reserved for the states.
As a democratic republic, the power of the government rests in the
174
hands of the United States citizens. More specifically, through voting,
the public is able to hold incumbents accountable for the policy
175
decisions they make. As a result, incumbents work to respond to the
public’s interests and demands, and thus, public interests shape public
176
policy. In the case of compulsory vaccination laws, incumbent
accountability is a very attractive privilege because if a state legislature
makes a decision regarding public health that is contrary to the public
interest, the public is able to resolve the problem via the ballot box. In
summary, the public has recourse through the electoral process.
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This type of accountability does not exist with federal agencies, at
least not to the same extent that state legislatures can be held
177
178
accountable. Some argue that there is Presidential accountability. In
other words, if an individual citizen has an issue with an action taken by
an administrative agency, he or she can raise that issue in the next
Presidential election. However, the relationship between the President’s
accountability and for example, the Secretary of the Department of
Health and Human Service’s accountability seems attenuated at best and
hardly satisfactory. This is particularly apparent to the mother whose
daughter has just been ordered to receive the HPV vaccine before she is
permitted to enter the sixth grade.
That said, perhaps compulsory vaccination laws fit well within the
area of lawmaking for which federal agencies were designed. Courts
and commentators have argued that “agencies are better situated to
179
address technical and scientific issues on the ‘frontiers of science,’”
and in fact, agencies originated with one strength in mind: expertise in
180
particular policy areas that are uniquely technical. In effect, agencies
exist for the very purpose of providing the expertise that legislatures
181
lack. This specialization is reflected in agency structures, which have
a small staff of appointed officials coupled with a large staff of
182
technological and scientific experts.
Although agencies may have little direct accountability, that
problem can be mitigated. Congress can exert additional authority over
administrative agencies by shaping their authoritative boundaries
183
through legislation. Additionally, accountability can be assured
184
through proper oversight.
Administrative law is a complex area, and this Article does not
provide a solution to the question of whether a federal agency or a state
legislature is better adapted to decide if a given compulsory vaccination
law should be passed. However, addressing the issue of accountability
highlights the need to take administrative law into consideration when
177
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determining who should be making compulsory vaccination laws.

CONCLUSION
The HPV vaccine stands front and center in a long line of vaccines
for which compulsory vaccination will be proposed and subsequently
debated. The HPV vaccine is not unique in its controversy; it is only the
first of many vaccines that exist in a type of purgatory where
compulsory vaccination is not obvious, but at the same time, is not
completely implausible either.
With the rapid development of science and technology, drug and
biologic manufacturers will continue to discover vaccines for a myriad
of different diseases, ranging from the most contagious to the
completely incommunicable, from the severely life-threatening to the
borderline innocuous. As it stands, the current process inadequately
deals with those vaccines that do not fit squarely into the protocol
defined in Jacobson.
Currently, state legislatures have seemingly limitless power to
mandate vaccines, even when they are neither contagious nor largely
life-threatening. What is more concerning is that state legislatures’
decisions seem largely driven by social and economic demands that
they readily succumb to in an effort to earn constituent votes. Should
compulsory HPV vaccine laws be upheld, there is the possibility that
vaccination policy will cascade down a slippery slope, at the bottom of
which state legislatures have the ability to strip individuals of their
privacy rights for unwarranted public health policies.
Somehow, the current system must be cleansed of its biases, but at
the same time, no suitable substitute appears readily available. It seems
that government agencies and professional medical associations are
haunted by similar industry pressures as state legislatures. To delegate
authority to the CDC, for example, may only serve to perpetuate biased
decision-making when it comes to compulsory vaccination laws. At the
same time, the CDC and the FDA are bastions of expertise and
knowledge that could prove instrumental in shifting the focus of vaccine
law from socio-economic concerns to scientific-technical concerns.
Perhaps the solution is to foster more collaboration between federal
agencies and state legislatures rather than to provide single-handed
authority to either entity. Instead of the CDC and ACIP disseminating
isolated recommendations upon which state legislatures must
impetuously rely, the CDC and state legislatures could collaborate to
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develop comprehensive legislation drafted with the perspectives of
multiple disciplines in mind. After all, most states already adhere to
CDC recommendations, so making the process more informed would
only serve to bolster the quality of state legislation.
For clarification, this Article does not make any conclusions as to
whether the HPV vaccine should be mandatory in international settings.
Certainly, the need for the government to protect public health and
safety may be greater in areas where access to medical attention
(including secondary prevention methods, such as the Pap smear) is
limited, where gender discrimination prohibits adequate reproductive
health care, and where cost (especially with on-patent drugs) is a
limiting factor for individuals in making health care decisions. The topic
of international mandatory vaccination is reserved for future discussion.
Further, this Article does not condemn the HPV vaccine. On the
contrary, this Article supports the determinations of the FDA, CDC, and
ACIP, which recommend the HPV vaccine where appropriate.
However, this Article does advocate for sound public health policies
that are not motivated by politics or bureaucracy but instead find their
basis in rigorous and legitimized scientific study and assessment. State
representatives’ inability to objectively assess the HPV vaccine has
undermined the vaccine’s immense potential health benefits and
distracted law-makers from their true obligations: to make decisions that
are in the best interest of the public health and safety.

